Antihemophilic Factor Recombinant

Data at EAHAD 2021 Highlight Value of Takeda’s Leading Hematology Portfolio in Clinical Settings and Commitment to Patient-Focused Advancements

Osaka, Japan:  − Seven Year Data Reinforce Long-term Efficacy and Safety Review of ADVATE (Antihemophilic Factor [Recombinant]) − Abstracts Support…

Read More »